- Dec Font Size
- Reset Text Size
- Inc Font Size
Geomatrix is a registered trademark of Jagotec AG. Shionogi Inc.’s use of the Geomatrix technology is under license from SkyePharma.
The Control You Expect
Proven efficacy in lowering systolic and diastolic pressure1
Prospective randomized, double-blind, double-dummy, dose-titration, 8-week study of 214 patients with mild to
moderate hypertension (DBP 95-114mmHg), comparing nisoldipine cc 10-40 mg to amlodipine 5-10 mg QD. The
primary efficacy endpoint was reduction in sitting trough DBP; secondary efficacy endpoints were reductions in
sitting trough SBP and heart rate. The small differences between treatments were not statistically significant
(p=0.37 and p=0.38, respectively).
The Control You Want
Once-a-day dosing provides 24-hour control2
Indication:
SULAR is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
Important Safety Information:
The most common adverse events, reported in US placebo-controlled trials, were peripheral edema, headache, and dizziness. In rare cases, some patients, particularly those with severe obstructive coronary artery disease, have developed increased frequency, duration, and/or severity of
angina, or acute myocardial infarction on starting calcium channel blocker therapy or at the time of dosage increase. Safety of SULAR in patients with heart failure has not been established. SULAR should be administered cautiously in patients over the age of 65 and in those with severe
hepatic dysfunction. Because nisoldipine, like other vasodilators, decreases peripheral vascular resistance, careful monitoring of blood pressure during the initial administration and titration of SULAR is recommended. SULAR should not be taken with grapefruit products.
Please click here for full prescribing information.
Your Healthcare Provider can give you more information about Sular or call (800) 849-9707 ext 1454. Ask your Healthcare Provider if Sular may be right for you.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
Images are for illustrative purposes only.
* Norvasc is a registered trademark of Pfizer Inc.
References: 1. Marazzi P. A study to demonstrate the equivalence in efficacy and safety of once-daily nisoldipine CC and amlodipine in the treatment of mild to moderate hypertension. Acta Therapeutica. 1996;22:23-35. 2. Punzi HA, Noveck R, Weiss RJ, et al. Are there differences in the effects of long-acting calcium antagonists on ambulatory blood pressure? Extended-release nisoldipine versus amlodipine as a model. Blood Press Monit. 1998;3:267-272.
